Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Further, the company’s board will also consider the declaration of 2nd interim dividend, if any, on the company’s equity shares for FY26.
Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. The company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.
The company’s consolidated net profit jumped 24.4% to Rs 132.40 crore on 11.3% increase in net sales to Rs 669.80 crore in Q1 FY26 over Q1 FY25.
Accurate identification of cancer spread to lymph nodes is vital in determining the stage and treatment path for patients. If the spread of cancer to the lymph nodes is left undetected, it can allow the disease to progress to later stages, increasing the risk of metastasis to distant organs and significantly reducing survival rates. Therefore, the identification of occult metastases in patients with early-stage cancer could have a substantial clinical impact on treatment planning and optimal therapy for patients with cancer.